Browse by author
Lookup NU author(s): Dr Carmela Ciardullo, Erhan Aptullahoglu, Dr Laura Woodhouse, Dr Wei-Yu Lin, Dr Jonathan Wallis, Dr Helen Marr, Dr Elaine WillmoreORCiD, Professor John LunecORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Chronic lymphocytic leukemia is a clinically heterogeneous haematological malignancy which is ~90% TP53 wild-type at diagnosis. As a primary repressor of p53, targeting of mouse double-minute-2 homolog (MDM2) is an attractive therapeutic approach for nongenotoxic reactivation of p53. Since discovery of the first MDM2 inhibitor, Nutlin-3a, newer potent and bioavailable compounds have been developed. Here, we tested the secondgeneration MDM2 inhibitor, RG7388, in patient-derived chronic lymphocytic leukemia cells and normal cells, examining its effect on the induction of p53-transcriptional targets. RG7388 potently decreased viability in p53-functional chronic lymphocytic leukemia cells whereas p53-non-functional samples were more drug-resistant. RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathway of apoptosis, as well as MDM2. A slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that chronic lymphocytic leukemia cells are primed for p53-dependent apoptosis. Consequently, RG7388 led to a concentration-dependent increase in caspase-3/7 activity and cleaved PARP. Importantly, we observed a preferential pro-apoptotic signature in chronic lymphocytic leukemia cells but not in normal blood and bone marrow cells, including CD34+ haematopoietic cells. These data support the further evaluation of MDM2 inhibitors as a novel additional treatment option for patients with p53-functional chronic lymphocytic leukemia.
Author(s): Ciardullo C, Aptullahoglu E, Woodhouse L, Lin WY, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J
Publication type: Article
Publication status: Published
Journal: Haematologica
Year: 2019
Volume: 104
Issue: 12
Pages: 2429-2442
Online publication date: 19/04/2019
Acceptance date: 16/04/2019
Date deposited: 27/06/2019
ISSN (print): 0390-6078
ISSN (electronic): 1592-8721
Publisher: Ferrata Storti Foundation
URL: https://doi.org/10.3324/haematol.2018.206631
DOI: 10.3324/haematol.2018.206631
PubMed id: 31004033
Altmetrics provided by Altmetric
